TORONTO, June 18, 2018 (GLOBE NEWSWIRE) — BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) today announced that its subsidiary, Belgravia Dermatology Inc. (“Belgravia Dermatology”) has completed the selection of initial drug targets and biological markers for its pre-clinical work in cannabinoid based dermatological treatments for unmet medical needs. The Company’s indications of interest include acne, atopic dermatitis, and psoriasis. The initial focus of product development is acne.
In addition to having identified drug targets and molecular biomarkers for unmet medical needs in acne, the Company is now defining specific drug delivery techniques which will allow for consistent dosing, a clearly defined therapeutic window for intradermal drug delivery, and the buttressing of intellectual property through correlating highly effective intradermal drug delivery technology with active pharmaceutical ingredients.
Dr. Sam Hanna, a well-known dermatologist with many years of medical and clinical research experience, and Chief Medical Officer of Belgravia Dermatology stated: “While there are many drugs available in the market to treat acne, these drugs often induce irritancy or are incompletely effective. There is a need for the development of drugs with novel mechanisms of action to target acne, with high efficacy and safety profiles. As our understanding of the endogenous endocannabinoid system has evolved, we realized this complex regulator of multiple physiological processes can likely be manipulated to influence several fundamental aspects of skin balance.
Dr. Hanna continued: “Based on our research to date, we have now identified specific cannabinoid receptors of interest including those which are neither CB-1 nor CB-2 receptors. The effects of activation or suppression of these receptors appears to include down-regulation of lipid production, the down-regulation of sebocyte proliferation, and the down-regulation of skin inflammation. The next steps for Belgravia Dermatology involve the finalization of delivery mechanisms, the filing of Intellectual Property incorporating active pharmaceutical ingredients and delivery technologies, and the further confirmation of research through cell line work. Various relevant cell lines are readily available.”
Mr. Mehdi Azodi, President and Chief Executive Officer of Belgravia, and Chairman and President of Belgravia Dermatology stated: “We are pleased to be advancing our dermatology subsidiary under the guidance of Dr. Hanna. We are currently looking to establish relationships with laboratories with licensed narcotics dealer accreditation, and with formulators of polymeric delivery systems.”
Belgravia Capital International Inc. is focused on its three core business divisions: Incubation, Investments and also Royalties. Belgravia will also develop new companies with a focus on the legal medical cannabis industry. The Incubation division will provide services to support the development of early-stage companies in the legal Cannabis space and other technologies as well as mineral and resources. Belgravia Holdings, the Investments division, invests in various private and public companies with a focus on legal medical cannabis, technology, and, on an opportunistic basis, resources. For more information, please visit www.belgraviacapital.ca.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as “may”, “will”, “expect”, “anticipate”, “believe”, “continue”, “potential” or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding planned investment activities & related returns, trends in the markets for fertilizers and medicinal or recreational use of cannabis, the timing or assurance of the legalization of recreational cannabis, the timing for completion of research and development activities, the potential value of royalties from water and other resources, and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, the completion, results and timing of research undertaken by the Company, risks associated with resource assets, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, the uncertainty of obtaining additional financing, and risks associated with cannabis use for medicinal or recreational purposes. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
For More Information, Please Contact:
President & CEO